Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6250
Source ID: NCT00604656
Associated Drug: Insulin Aspart
Title: Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1
Interventions: DRUG: insulin aspart
Outcome Measures: Primary: Insulin aspart antibodies, After 6 months treatment | Secondary: Occurrence of adverse events|Incidence of hypoglycaemic episodes|HbA1c
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 241
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-05-05
Completion Date: 2004-01-29
Results First Posted:
Last Update Posted: 2017-03-01
Locations: Novo Nordisk Investigational Site, Hradec Králové, 500 36, Czech Republic|Novo Nordisk Investigational Site, Praha 5, 15018, Czech Republic|Novo Nordisk Investigational Site, Bad Kreuznach, 55545, Germany|Novo Nordisk Investigational Site, Bad Neuenahr-Ahrweiler, 53474, Germany|Novo Nordisk Investigational Site, Diez, 65582, Germany|Novo Nordisk Investigational Site, Frankfurt, 60325, Germany|Novo Nordisk Investigational Site, Friedrichsthal, 66299, Germany|Novo Nordisk Investigational Site, Karlsruhe, 76133, Germany|Novo Nordisk Investigational Site, Marktheidenfeld, 97828, Germany|Novo Nordisk Investigational Site, Marl, 45770, Germany|Novo Nordisk Investigational Site, Oberursel, 61440, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, 66780, Germany|Novo Nordisk Investigational Site, Saarbrücken, 66121, Germany|Novo Nordisk Investigational Site, Simmern, 55469, Germany|Novo Nordisk Investigational Site, Speyer, 67346, Germany|Novo Nordisk Investigational Site, St. Ingbert, 66386, Germany|Novo Nordisk Investigational Site, Würzburg, 97072, Germany|Novo Nordisk Investigational Site, Budapest, 1096, Hungary|Novo Nordisk Investigational Site, Nyíregyháza, 4400, Hungary|Novo Nordisk Investigational Site, Cagliari, 09124, Italy|Novo Nordisk Investigational Site, Chiavari, 16043, Italy|Novo Nordisk Investigational Site, Citta' Di Castello, 06012, Italy|Novo Nordisk Investigational Site, Lucca, 55100, Italy|Novo Nordisk Investigational Site, Orvieto, 05018, Italy|Novo Nordisk Investigational Site, Parma, 43100, Italy|Novo Nordisk Investigational Site, Perugia, 06126, Italy|Novo Nordisk Investigational Site, Rimini, 47900, Italy|Novo Nordisk Investigational Site, Roma, 00128, Italy|Novo Nordisk Investigational Site, Roma, 00133, Italy|Novo Nordisk Investigational Site, Bytom, 41-902, Poland|Novo Nordisk Investigational Site, Mazowieckie, 09-400, Poland|Novo Nordisk Investigational Site, Radom, 26-600, Poland|Novo Nordisk Investigational Site, Warsaw, 03-242, Poland|Novo Nordisk Investigational Site, Wroclaw, 50-306, Poland
URL: https://clinicaltrials.gov/show/NCT00604656